RNA, U6atac small nuclear 38, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6ATAC38P profile across patient tissues and cancer cell-line models. RNU6ATAC38P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNU6ATAC38P is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, RNU6ATAC38P RNA expression shows 8,886 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KIRC, THCA, and LIHC as cancer lineages where RNU6ATAC38P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6ATAC38P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6ATAC38P survival associations across molecular data types. RNU6ATAC38P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6ATAC38P RNA expression–survival associations across cancer types. High RNU6ATAC38P expression shows unfavorable associations in KIRC, THCA, KICH, LUSC, HNSC and PCPG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNU6ATAC38P RNA expression.
This table summarizes RNU6ATAC38P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6ATAC38P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6ATAC38P shows lower tumor expression in THCA and LUSC and higher tumor expression in COAD, PAAD, LUAD and KIRC. The THCA box plot shows higher RNU6ATAC38P RNA expression in normal versus tumor tissue (log2 FC = −0.234, t-test p < 0.001).
This table shows molecular features associated with RNU6ATAC38P in patient tissues and cancer cell lines. In patient samples, RNU6ATAC38P shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
